DALIAN, China -- China continues to struggle in developing a homegrown mRNA vaccine against COVID-19, with its front-runner failing to reach the market by the end of last year as hoped and now showing disappointing results against the highly infectious omicron variant.
The messenger RNA-based ARCoV vaccine candidate developed by Abogen Biosciences, Walvax Biotechnology and the Academy of Military Medical Sciences, now in Phase 3 clinical trials, encountered a snag shown in a paper published last month in the journal Cell Research.
